Cargando…
Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection
The prevalence of Mycobacterium avium complex-pulmonary disease (MAC-PD) has become a growing concern worldwide, and current treatments involving macrolides (clarithromycin [CLR] or azithromycin), ethambutol, and rifampicin have limited success, highlighting the need for better therapeutic strategie...
Autores principales: | Lee, Ju Mi, Kim, Lee-Han, Kim, Su-Young, Jhun, Byung Woo, Lee, Wonsik, Shin, Sung Jae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667338/ https://www.ncbi.nlm.nih.gov/pubmed/37996500 http://dx.doi.org/10.1038/s41598-023-48001-y |
Ejemplares similares
-
Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium Complex and Mycobacterium abscessus clinical isolates
por: Kim, Su-Young, et al.
Publicado: (2021) -
In vitro and intracellular activities of novel thiopeptide derivatives against macrolide-susceptible and macrolide-resistant Mycobacterium avium complex
por: Park, Jiyun, et al.
Publicado: (2023) -
A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the Mycobacterium avium Complex
por: Lee, Ju Mi, et al.
Publicado: (2021) -
Characteristics of Circulating CD4(+) T Cell Subsets in Patients with Mycobacterium avium Complex Pulmonary Disease
por: Han, Sun Ae, et al.
Publicado: (2020) -
Modulating macrophage function to reinforce host innate resistance against Mycobacterium avium complex infection
por: Park, Hyun-Eui, et al.
Publicado: (2022)